Drug intelligence / Profile preview

mRNA cytokine lipid nanoparticle

Development stage: Preclinical
Lead developer: InhaTarget Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Inhalation

Overview

mRNA cytokine lipid nanoparticle (mRNA-cytokine-LNP) is an inhaled mRNA-based therapeutic delivered via lipid nanoparticles (LNPs), under development by InhaTarget Therapeutics for the treatment of inflammatory and fibrotic lung diseases. The therapeutic utilizes mRNA encapsulated in LNPs to target lung macrophages and fibroblasts, modulating cytokine pathways to resolve pro-inflammatory or pro-fibrotic signaling directly within the pulmonary microenvironment. It is designed for non-invasive, localized delivery to the lungs to maximize therapeutic efficacy while minimizing systemic side effects.

Other names: mRNA-cytokine-LNP

Beyond the preview

Go deeper on mRNA cytokine lipid nanoparticle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA cytokine lipid nanoparticle.